Changes of regulatory T cells in Graves’ disease

Abstract

The immune mechanism of Graves’ diseases (GD) and the roles of regulator T cells were investigated. In 32 patients with GD (GD group) and 20 healthy volunteers (control group), flow cytometry was used to detect the proportion of CD4⁺CD25⁺ cells, MACS to isolate CD4⁺ CD25⁺ cells, RT-PCR to assay the expression of FOXP3, and ELISA to test the level of IL-10, respectively. It was found that there was no significant change in the proportion of CD4⁺CD25⁺ T cells between GD group and control group (P>0.05), while secretion of IL-10 and expression of FOXP3 in GD group were lower than control group (P<0.01 and P<0.05, respectively). In conclusion, though the proportion of regulatory T cells of peripheral blood lymphocytes in the patients with GD, the functions of them were significantly weakened, which might be a pathogenic factor in GD.

Keywords

Graves’ disease / regulatory T cell / IL-10 / FOXP3

References

[1] HoriS., SakaguchiS.. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect, 2004, 6(8): 745-751

[2] GrilloM., MargolisF. L.. Use of reverse transcriptase polymerase chain reaction to monitor expression of intronless genes. Biotechniques, 1990, 9(3): 262

[3] SakaguchiS.. Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol, 2004, 22: 531-562

[4] JonuleitH., SchmittE.. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol, 2003, 171(12): 6323-6327

[5] von BoehmerH.. Mechanisms of suppression by suppressor T cells. Nat Immunol, 2005, 6(4): 338-344

[6] SundstedtA., O’NeillE. J., NicolsonK. S., et al.. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol, 2003, 170(3): 1240-1248

[7] PiccirilloC. A., LetterioJ. J., ThorntonA. M., et al.. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med, 2002, 196(2): 237-246

[8] KocjanT., WraberB., RepnikU., et al.. Changes in Th1/Th2 cytokine balance in Graves’ disease. Pflugers Arch, 2000, 440(5Suppl): R94-95

[9] BrunkowM. E., JefferyE. W., HjerrildK. A., et al.. Disruption of a new for khead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 2001, 27(1): 68-73

[10] HoriS., NomuraT., SakaguchiS.. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609): 1057-1061

[11] FontenotJ. D., GavinM. A., RudenskyA. Y.. Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. Nat Immunol, 2003, 4(4): 330-336

[12] WalkerM. R., KasprowiczD. J., GersukV. H., et al.. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4⁺CD25-T cells. J Clin Invest, 2003, 112(9): 1437-1443

[13] RamsdellF.. Foxp3 and natural regulatory T cells: key to a cell lineage?. Immunity, 2003, 19(2): 165-168